WallStreetZenWallStreetZen

NASDAQ: GERN
Geron Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for GERN

Based on 1 analyst offering 12 month price targets for Geron Corp

Min Forecast
$4.00+173.97%
Avg Forecast
$4.00+173.97%
Max Forecast
$4.00+173.97%

Should I buy or sell GERN stock?

Based on 1 analyst offering ratings for Geron Corp.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although GERN's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates GERN as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their GERN stock forecasts and price targets.

GERN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-05

1 of 1

Forecast return on equity

Is GERN forecast to generate an efficient return?

Company
98.35%
Industry
68.21%
Market
181.01%
GERN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GERN forecast to generate an efficient return on assets?

Company
38.94%
Industry
31.86%
GERN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GERN earnings per share forecast

What is GERN's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$0.04
Avg 2 year Forecast
$0.03
Avg 3 year Forecast
$0.04

GERN revenue forecast

What is GERN's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$233.4M+26.91%
Avg 2 year Forecast
$335.5M+82.43%
Avg 3 year Forecast
$486.9M+164.76%
GERN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GERN revenue growth forecast

How is GERN forecast to perform vs Biotechnology companies and vs the US market?

Company
37.47%
Industry
35.63%
Market
13.32%
GERN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GERN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GERN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GERN$1.46$4.00+173.97%Buy
XERS$5.44$11.25+106.80%Buy
CMPX$5.15$16.67+223.63%Strong Buy
AVBP$22.02$42.83+94.52%Strong Buy
VALN$10.32N/AN/A
View Top Biotech Stocks

Geron Stock Forecast FAQ

Is Geron Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: GERN) stock is to Buy GERN stock.

Out of 1 analyst, 0 (0%) are recommending GERN as a Strong Buy, 1 (100%) are recommending GERN as a Buy, 0 (0%) are recommending GERN as a Hold, 0 (0%) are recommending GERN as a Sell, and 0 (0%) are recommending GERN as a Strong Sell.

If you're new to stock investing, here's how to buy Geron stock.

What is GERN's earnings growth forecast for 2026-2028?

(NASDAQ: GERN) Geron's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.08%.

Geron's earnings in 2026 is -$83,500,000.On average, 8 Wall Street analysts forecast GERN's earnings for 2026 to be -$28,312,074, with the lowest GERN earnings forecast at -$43,941,364, and the highest GERN earnings forecast at -$13,451,438. On average, 8 Wall Street analysts forecast GERN's earnings for 2027 to be $16,333,889, with the lowest GERN earnings forecast at -$62,773,377, and the highest GERN earnings forecast at $107,611,503.

In 2028, GERN is forecast to generate $22,867,444 in earnings, with the lowest earnings forecast at -$31,386,688 and the highest earnings forecast at $100,885,784.

What is GERN's revenue growth forecast for 2026-2028?

(NASDAQ: GERN) Geron's forecast annual revenue growth rate of 37.47% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.32%.

Geron's revenue in 2026 is $183,881,000.On average, 8 Wall Street analysts forecast GERN's revenue for 2026 to be $149,477,502,091, with the lowest GERN revenue forecast at $141,176,043,284, and the highest GERN revenue forecast at $157,452,283,120. On average, 8 Wall Street analysts forecast GERN's revenue for 2027 to be $214,877,111,979, with the lowest GERN revenue forecast at $180,973,083,072, and the highest GERN revenue forecast at $279,828,340,604.

In 2028, GERN is forecast to generate $311,849,168,208 in revenue, with the lowest revenue forecast at $231,588,922,185 and the highest revenue forecast at $505,684,388,073.

What is GERN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: GERN) forecast ROA is 38.94%, which is higher than the forecast US Biotechnology industry average of 31.86%.

What is GERN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year GERN price target, the average GERN price target is $4.00, with the highest GERN stock price forecast at $4.00 and the lowest GERN stock price forecast at $4.00.

The Wall Street analyst predicted that Geron's share price could reach $4.00 by Nov 5, 2026. The average Geron stock price prediction forecasts a potential upside of 173.97% from the current GERN share price of $1.46.

What is GERN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: GERN) Geron's current Earnings Per Share (EPS) is -$0.13. On average, analysts forecast that GERN's EPS will be -$0.04 for 2026, with the lowest EPS forecast at -$0.07, and the highest EPS forecast at -$0.02. On average, analysts forecast that GERN's EPS will be $0.03 for 2027, with the lowest EPS forecast at -$0.10, and the highest EPS forecast at $0.17. In 2028, GERN's EPS is forecast to hit $0.04 (min: -$0.05, max: $0.16).

What is GERN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: GERN) forecast ROE is 98.35%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.